Next Phase Newsletter

A family office located in New York City makes approximately 2 to 3 equity investments per year into healthcare companies located in the United States. The firm does not have an average investment size as it depends on the opportunity, however – the firm looks to take a control seat when doing so as they are a value added investor.

The firm is interested in services, HCIT, diagnostics, medical devices, and auxiliary services. The firm is very opportunistic within these areas and they are agnostic with regard to indication areas. The firm looks for growth stage companies located in the United States that are generating profits or close to doing so. The firm is not interested in long term deals and prefers companies with 48 months of an exit.

The firm has no explicit management team requirements as the firm is a value-added investor and takes an active role in its portfolio companies. The firm requests a board seat and provides its portfolio companies with experienced talent to help improve operations.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A specialty pharmaceutical company headquartered in Tokyo, Japan focuses on pharmaceuticals, medical devices, and agro-veterinary products. The firm has strong experience in developing and commercializing novel pharmaceuticals and medical devices in the fields of orthopedics, dermatology and surgery. The firm is currently seeking R&D collaboration and in-licensing opportunities globally as well as Japan-local marketing alliance.

Currently the firm is looking for innovative therapeutic products in the following areas: orthopedics with a focus on inflammation and pain, including RA/OA/arthritis pain/low-back pain; dermatology including dermatitis/acne/psoriasis; and mycology including topical and systemic treatments. The firm is also interested in peri-surgical medical devices as well as ophthalmology and niche market products.

The firm seeks to partner with publicly and privately held life science companies with experienced management teams and innovative technologies in the abovementioned areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An early-stage investment and development firm located in the US Mountain West has more than $300 million in assets and operates under an “Evergreen” structure. The firm is flexible in investment size and structure, but prefer initial investments in the $1M – $3M range.

The firm invests in medical devices, therapeutics, diagnostics and research tools. RCT focuses on medical devices that can be approved under the 510(k) guidelines, and prefers therapeutic product generating platforms and research tools platforms. For therapeutics, RCT prefers investments at an early-stage, from pre-clinical up to Phase I.

The firm seeks to invest in small, early-stage companies with a lean but strong and qualified management / execution team. The firm prefers to invest in companies in the U.S., but will consider opportunities in Europe, Israel and Australia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Chinese venture capital firm with offices in Shanghai and Beijing has raised two funds to date, with its second fund raised in 2011 at USD 125 million. The firm mainly invests in early stage high-growth technology businesses but has expanded its interest into medical technology. The firm generally allocates USD 5-10 million per company. The firm focuses 70% domestically and 30% on the US. The firm is interested in companies that have a China angle, specifically, developing products relevant to the Chinese market. The firm is actively seeking new investment opportunities.

In healthcare, the firm is currently looking for medical devices that address a large market in China. IVD and devices with a software component are of high interest. The firm is opportunistic in terms of subsectors and considers all classes of devices. In terms of the stage of development, the firm prefers devices that have regulatory approval (preferably CE mark); ideally, the device should be ready for CFDA. However, the firm will also consider devices in the final stages of clinical trials.

The firm can invest globally but the firm is only interested in companies that have a China angle, i.e. Chinese-led and/or developing products for the Chinese market. The firm has no revenue requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An investment firm based in Taiwan is interested in the life sciences and will target new investments from a new USD 100 million fund. The firm can sometimes leverage different funds to invest. The fund’s target investment size is USD 3-5 million per company and USD 1-1.5 million for early stage companies. Capital allocation per company will not exceed 10% of the fund. The firm seeks companies in Asia-Pacific, including the US and Japan. The firm is actively seeking new investment opportunities.

In the life sciences, the firm is interested in therapeutics, medical devices, and diagnostics. For therapeutics, the firm will consider a broad range of modalities including small molecules and biologics with an emphasis on stem cell, immunotherapy, and CNS therapies. The firm is opportunistic in terms of indications. For companies in Asia, the firm is agnostic to the phase of development. For overseas deals, the firm is currently looking for preclinical to phase 2 assets. The firm prefers candidates with in-human data and are conducting clinical trials in the US, while this is not a requirement.

For devices, the firm considers minimally invasive class III devices in the cardiovascular and cancer space that have prototype and have obtained proof-of concept. For diagnostics, the firm is interested in genomics and big data analytics. Recently there is an interest in the cosmetics and supplements area, and the firm is seeking acquisition opportunities to commercialize products through distribution channels within its network.

The firm only invests in private companies and aims to be a minority investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A pharma firm established a new corporate venture arm in 2015.  The firm is based in London and invests from a $30M fund, typically contributing $250K-$3M to a finacing round. The firm will participate in rounds for digital health companies at all stages, as early as seed and through later venture rounds. They are open to working with companies globally, but focus on US-based investments.

Within digital health, the firm is seeking digital medicine devices and wearables that address chronic or respiratory diseases, oncology, and consumer health. Past investments in the space include a wearable nicotine delivery device with integrated software and data analytics component to aid in smoking cessation.

The firm prefers to work with full management teams with a track record in the space. A strong business plan should be in place, and companies should have IP around their products.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An Asia-based investment firm backed by a large bank is managing a US$60M healthcare fund raised in 2014.  The firm invests in several sectors across healthcare. The firm generally participates in Series A or B rounds and prefers a clear exit in less than 5 years. The firm is open to both leading and co-investing. Typical equity investments range from US$2-10M. The firm currently focuses 60% on regional-based deals and 40% on China- and US-based deals.

The firm considers therapeutics and medical devices. Within therapeutics, the firm is open to all modalities including small molecules, biologics, cell therapy and gene therapy with a focus on cancer therapies. The firm would also consider R&D services, healthcare services, and healthcare IT products such as EMR management software. The firm seeks to invest in venture stage companies in Series A or B rounds.

The firm prefers to back entrepreneurs with a successful track record. The firm typically requests a board seat in their portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com